Participants 52 127 5
postmenopausal women with advanced, hormone-receptor-positive breast cancer
Participants 464 517 6
patients with hormone-receptor-positive breast cancer
Participants 539 588 4
phase 2 trial in outpatient clinics and hospitals
Participants 602 743 7
postmenopausal women with hormone-receptor-positive, locally advanced or metastatic breast cancer previously treated with endocrine treatment
Participants 1437 1536 6
We screened 189 patients and enrolled 156 (106 in the ganitumab group and 50 in the placebo group).
Participants 2501 2601 4
 treatment in women with previously treated hormone-receptor-positive locally advanced or metastatic
